Results 201 to 210 of about 3,069,601 (247)

Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer

MedComm, Volume 7, Issue 10, October 2026.
Mesothelin overexpression activate important pathways like nuclear factor k‐light‐chain‐enhancer of activated B cells (NF‐κB) and interleukin‐6 (IL‐6). This in turn causes numerous cancers, such as pancreatic and ovarian cancers. MSLN‐targeting immunotherapies, like monoclonal antibodies, have shown efficacy.
Manoj Kumar Gupta, Ramakrishna Vadde, Ganji Purnachandra Nagaraju   +2 more
wiley   +1 more source

The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study. [PDF]

Oncologist
Neola G, Flauto F, Caso C, Montuori G, Maruzzo M, Lai E, Banna GL, Maffezzoli M, Rizzo M, Massari F, Mollica V, Scagliarini S, Conteduca V, Giannatempo P, Rametta A, Maiorano BA, Facchini G, Lenci E, Tambaro R, Grillone F, Bosso D, Crocetto F, Imbimbo C, Servetto A, Bianco R, Formisano L.   +25 more
europepmc   +1 more source

A Novel Technique for the Distal Ureter and Bladder Cuff During Nephroureterectomy: Thulium Laser Resection

Trends in Urology &Men's Health, Volume 17, Issue 5, October 2026.
ABSTRACT The aim of this study was to evaluate the safety and feasibility of a novel technique involving the use of the two‐micron thulium fibre laser (Tm‐laser) to perform bladder cuff excision (BCE) during radical nephroureterectomy (RNU). We conducted a retrospective review of all patients undergoing RNU with BCE for upper tract urothelial carcinoma
Shravankrishna Ananthapadmanabhan, Jeremy Saad, Hong Soh, Darius Ashrafi, Hodo Haxhimolla   +4 more
wiley   +1 more source

Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer. [PDF]

Nat Commun
Chen Z, Tang X, Eichholz JE, Mcpherson A, Thomas J, Nagar K, Rustgi N, Christin JR, Kuo F, Gao S, Jiang H, Luo J, Ostrovnaya I, Basar M, Pietzak E, Coleman JA, Berger MF, de Stanchina E, Shah SP, Mohibullah N, Aggen DH, Rosenberg JE, Chandarlapaty S, Shen MM, Al-Ahmadie H, Iyer G, Kim K, Solit DB.   +27 more
europepmc   +1 more source

INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol

BJU International, Volume 138, Issue 4, Page 607-619, October 2026.
Background High‐risk non‐muscle‐invasive bladder cancer (HRNMIBC) has a variable prognosis, managed predominantly by local surgical resection and intravesical Bacillus Calmette–Guérin (BCG), or radical cystectomy (RC). Current treatments are poorly tolerated, have supply limitations and often fail to control the disease.
Ruby Lister‐Whelan, Ethan Senior, Jessica Kendall, Jamie B. Oughton, Fiona Collinson, Jon Griffin, Rachel Hubbard, Steven Kennish, Aidan Noon, Derek J. Rosario, Irbaz B. Riaz, Julie Telliez, James W. F. Catto, Syed A. Hussain   +13 more
wiley   +1 more source

Outcomes with Avelumab Maintenance Treatment for Advanced Urothelial Cancer in a US Patient Cohort. [PDF]

Curr Oncol
Carson K, Mahmoudpour SH, Ike C, Monzon S, Fragkogianni S, Kearney M.   +5 more
europepmc   +1 more source

Immediate intraoperative detrusor muscle status at primary transurethral resection of bladder tumour: a prospective, blinded, paired cohort, feasibility study using fluorescence confocal microscopy (IB1‐LaserComplete study)

BJU International, Volume 138, Issue 4, Page 705-713, October 2026.
Objectives To evaluate ex vivo fluorescence confocal microscopy (FCM) for immediate detrusor muscle (DM) assessment during primary transurethral resection of bladder tumour (TURBT). Patients and Methods This prospective, blinded, paired‐cohort feasibility study enrolled consecutive patients undergoing primary TURBT for suspected non‐muscle‐invasive ...
Martin J. Connor, Archana Gopalakrishnan, Nikhil Mayor, Eva Bolton, Sami Hamid, Sai Kalpitha Reddy, Tayla Perreau, Eslam Maher, Alexander Light, Samuel Morris, Jiten Jaipura, Mariana Bertoncelli Tanaka, Norma Gibbons, Archie Hughes‐Hallett, Hashim U. Ahmed, Rakesh Heer, Andrew Smith, David Hrouda, Anna Silvanto, Mona El‐Bahrawy, Mathias Winkler   +20 more
wiley   +1 more source

Longitudinal genome-wide aneuploidy measurements in circulating cell-free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer. [PDF]

Mol Oncol
Salhi Y, Makrodimitris S, van Wilpe S, Te Paske I, de Weerd V, Beaufort CM, Westgeest HM, Voortman J, Aarts MJB, Rijnders M, van der Veldt AAM, de Wit R, Mehra N, Wilting SM, Robbrecht DGJ.   +14 more
europepmc   +1 more source

NTAQ1 Promotes Hepatocellular Carcinoma Growth by Facilitating the Protein Degradation of the Tumor Suppressor PRDM2

Cancer Science, Volume 117, Issue 10, Page 2803-2818, October 2026.
Copy number variation analysis in The Cancer Genome Atlas identified NTAQ1 as a potential driver of HCC progression. NTAQ1 accelerates tumor growth by promoting the degradation of the tumor suppressor protein PRDM2, thereby impairing DNA repair and suppressing apoptosis. These findings indicate that NTAQ1 could be a valuable target for the treatment of
Tomohiko Ikehara, Hajime Otsu, Taro Tobo, Kiyotaka Hosoda, Tadashi Abe, Masahiro Hashimoto, Yusuke Nakano, Katsushi Dairaku, Yuya Ono, Yuki Miyata, Chihiro Matsumoto, Takanari Tatsumi, Satoshi Higuchi, Takashi Ofuchi, Akinori Tsujimoto, Yuki Ando, Qingjiang Hu, Yusuke Yonemura, Akira Shimizu, Takaaki Masuda, Yuji Soejima, Koshi Mimori   +21 more
wiley   +1 more source

Efficacy and safety of combining radiotherapy with first-line chemotherapy and immunotherapy for local advanced/metastatic urothelial cancer: a propensity score matching analysis. [PDF]

Front Immunol
Qin J, Zhou H, Li X, Yin H, Deng H, Luo Y, Chen Y, Yin Y, Zhou R, Zhan N, Zheng Y, Zhang T, He W.   +12 more
europepmc   +1 more source